Research Reference
Cagrilintide
Long-acting amylin analog — satiety and weight management
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Cagrilintide is a long-acting amylin analog currently under investigation for chronic weight management. As one half of the CagriSema combination (paired with semaglutide 2.4 mg), it represents a new approach to obesity pharmacotherapy.
Cagrilintide is not FDA-approved and remains investigational.
Community-documented protocol: 250 mcg subcutaneous in the morning, 3 days per week, for 8-week cycles — far below the 2.4 mg weekly clinical trial dose, reflecting conservative research-peptide practice.
Side Effects & Safety
Per REDEFINE 1 and the Lau (2021) phase 2 program, trial-reported adverse events include:
- Nausea — most common (25–40%); peaks during dose escalation, typically mild-moderate
- Diarrhea — 10–20%, usually transient
- Constipation — 8–15%
- Vomiting — 5–15%, more frequent at higher doses
- Injection site reactions — 5–10%, mild erythema and pruritus
- Decreased appetite — 5–12%, related to mechanism of action
- Pancreatitis — rare but monitored (as with all GLP-1/amylin agents)
- Gallbladder events — cholelithiasis reported, consistent with rapid weight loss
Trial data describes dose titration as central to tolerability.
Research Basis
Phase 2 monotherapy (Lau et al., 2021): 706 adults with overweight/obesity across 57 sites. Cagrilintide 4.5 mg produced 10.8% mean weight loss at 26 weeks, comparable to liraglutide 3.0 mg. Clear dose-response relationship observed from 0.3 mg to 4.5 mg.
REDEFINE 1 — CagriSema phase 3 (Aronne et al., 2025): CagriSema 2.4/2.4 mg produced 22.7% mean weight loss at 68 weeks vs 2.1% placebo. 60% of participants achieved 20% or more weight loss — a threshold historically associated with bariatric surgery outcomes.
REDEFINE 2 — CagriSema in T2D (Lingvay et al., 2025): Significant weight loss and glycemic improvement in adults with overweight/obesity and type 2 diabetes.
Phase 2 CagriSema in T2D (Frias et al., 2023): CagriSema produced superior weight loss and glycemic improvement vs either monotherapy over 32 weeks.